PALOVAROTENE - 3 mg ( DrugBank: Palovarotene )


1 disease
IDDisease name (Link within this page)Number of trials
272Fibrodysplasia ossificans progressiva1

272. Fibrodysplasia ossificans progressiva


Clinical trials : 39 Drugs : 38 - (DrugBank : 7) / Drug target genes : 27 - Drug target pathways : 95
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-002541-29-DE
(EUCTR)
29/09/2017A clinical trial to evaluate the Efficacy and Safety of Oral Palovarotene as a treatment for Fibrodysplasia Ossificans Progressiva (FOP)A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) - MOVE Trial Fibrodysplasia Ossificans Progressiva (FOP)
MedDRA version: 20.0;Level: PT;Classification code 10068715;Term: Fibrodysplasia ossificans progressiva;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: PALOVAROTENE - 1mg
INN or Proposed INN: PALOVAROTENE
Other descriptive name: PALOVAROTENE
Product Name: PALOVAROTENE - 1.5mg
INN or Proposed INN: PALOVAROTENE
Other descriptive name: PALOVAROTENE
Product Name: PALOVAROTENE - 2 mg
INN or Proposed INN: PALOVAROTENE
Other descriptive name: PALOVAROTENE
Product Name: PALOVAROTENE - 2.5 mg
INN or Proposed INN: PALOVAROTENE
Other descriptive name: PALOVAROTENE
Product Name: PALOVAROTENE - 3 mg
INN or Proposed INN: PALOVAROTENE
Other descriptive name: PALOVAROTENE
Product Name: PALOVAROTENE - 4 mg
INN or Proposed INN: PALOVAROTENE
Other descriptive name: PALOVAROTENE
Product Name: PALOVAROTENE - 5 mg
INN or Proposed INN: PALOVAROTENE
Other descriptive name: PALOVAROTENE
Product Name: PALOVAROTENE - 10 mg
INN or Proposed INN: PALOVAROTENE
Other descriptive name: PALOVAROTENE
Clementia Pharmaceuticals IncNULLNot RecruitingFemale: yes
Male: yes
80Phase 3United States;Spain;Russian Federation;United Kingdom;Italy;France;Canada;Argentina;Brazil;Australia;South Africa;Netherlands;Germany;Japan;Sweden